Cannabis in Midlife: The New Gray Zone and What You Need to Know
Cannabis use among adults 50 and older has increased more than 250% over the past decade. Most midlife users believe it is safer than alcohol and medically supported. The research on anxiety, sleep, cognition, dependence, and the aging brain tells a more complicated story one that midlife adults are rarely given.
By Dr. Julie Rashkis, Psy.D. | Licensed Psychologist | Menopause Society Certified Practitioner | therapyformidlife.com
'I started using cannabis about two years ago. My doctor actually suggested it, or at least didn't object when I mentioned it. I use an edible every evening for sleep and anxiety. It works better than anything I've tried. I don't think of it as a drug in the same way as alcohol. It's legal where I live. It's natural. I'm not hurting anyone. But lately I've noticed I can't sleep at all without it, and my anxiety is worse during the day than it used to be. And my memory is bad, I don't know if that's related.'
This is the midlife cannabis story that is becoming increasingly common, and that clinical settings are often unprepared to address. Cannabis use among adults in their 40s, 50s, and 60s has increased more rapidly than in any other age group over the past decade. Most of these adults began using or returned to using cannabis in the context of legalization, with medical rationales (sleep, pain, anxiety), and with a risk perception substantially lower than their perception of alcohol. Many of them are correct that cannabis carries different risks than alcohol. The assumption that it carries no significant risks, or that the midlife brain processes it the same way a younger brain does is not supported by the current research.
This article provides the cannabis-specific gray zone analysis that the previous articles provided for alcohol: what the research shows about cannabis use in midlife adults, what the specific risks are for this age group, how cannabis use disorder presents differently from alcohol use disorder, and what honest clinical assessment of midlife cannabis use looks like.
The Scale of the Shift: What Is Actually Happening
The data on cannabis use in midlife and older adults is striking, and it represents one of the most significant behavioral health shifts of the past decade. The Monitoring the Future Panel Study found that past 12-month cannabis use among early midlife adults (ages 35 to 50) increased from 4.4% in 2014 to 26.6% in 2024; a near-sixfold increase in a decade.
Cannabis vaping in this age group reached historic highs in 2024, rising from 8.7% in 2023 to 10.9% in 2024. Among late midlife adults (ages 55 to 65), use has similarly increased dramatically over the same period.
Among adults 50 and older, the 2024 National Poll on Healthy Aging found that one in five adults over 50 reported past-year cannabis use. The most commonly reported reasons were relaxation (81%), sleep (68%), enjoyment (64%), pain (63%), and mental health or mood (53%). Critically, 44% of those using cannabis at least monthly had not discussed it with a healthcare provide, meaning that a substantial proportion of midlife cannabis users are making self-guided decisions about a pharmacologically active substance without clinical oversight.
A 2025 study in the International Journal of Mental Health and Addiction found that adults over 50 who used cannabis daily had 133% increased odds of reporting 14 or more days of poor mental health and 76% increased odds of reporting 14 or more days of poor physical health in the past 30 days. Among the same population, 17 to 22% reported tolerance (needing more to achieve the same effect) and 13% reported craving, both diagnostic criteria for cannabis use disorder, despite many not identifying their use asproblematic.
"Cannabis use among adults 50 and older has increased more than 250% over the past decade. One in five adults over 50 reports past-year use. Of monthly users, 44% have not discussed it with a healthcare provider. And, among daily users, 133% increased odds of 14+ days of poor mental health despite most users not identifying their use as a problem." — Monitoring the Future (2024); National Poll on Healthy Aging (2024); International Journal of Mental Health and Addiction (2025)
Why the Midlife Brain Is Specifically Vulnerable
Cannabis is not a benign substance, and its effects on the aging brain differ from its effects on younger brains in ways that most midlife users are not informed about. The assumptions that many midlife adults carry, formed when cannabis was primarily a recreational substance used in youth, do not accurately reflect what the current research shows about the aging brain's response to regular cannabis use.
______________________________________________
Vulnerability: Pharmacokinetic changes
What Is Happening: The aging body metabolizes THC more slowly. Body fat percentage increases with age, and THC is fat-soluble meaning it accumulates in fat tissue and is released slowly, extending duration of effects and intoxication
Why It Happens in Midlife: The same dose that produced a manageable effect at 35 may produce stronger and longer-lasting effects at 55. Older adults are more susceptible to THC-related impairment at equivalent doses than younger adults
______________________________________________
Vulnerability: Cognitive vulnerability
What is Happening: The Dunedin cohort study found that persistent cannabis users showed a 5.5-point IQ decline and reduced hippocampal volume by age 45, compared to infrequent users. Heavy cannabis use was linked to modest but significant declines in verbal memory by midlife in two large longitudinal studies
Why It Happens in Midlife: Midlife adults who are already concerned about cognitive aging including brain fog, word-finding and Alzheimer's risk, may be using cannabis in a way that compounds the very cognitive changes they fear
______________________________________________
Vulnerability: Cardiovascular effects
What is Happening: Cannabis acutely increases heart rate and blood pressure. Adults over 50 have higher baseline cardiovascular risk than younger adults. Research has documented cannabis-associated cardiac events including arrhythmia and myocardial infarction in older adults
Why It Matters in Midlife: A midlife adult with hypertension, diabetes, or other cardiovascular risk factors faces a different risk profile from cannabis use than a healthy 25-year-old
______________________________________________
Vulnerability: Drug-drug interactions
What Is Happening: Cannabis interacts with multiple commonly prescribed medications including blood thinners, antidepressants, seizure medications, and cardiac medications through cytochrome P450 enzyme pathways
Why It Matters in Midlife: Midlife adults are significantly more likely to be taking prescription medications than younger adults. Many are taking cannabis without disclosing it to their prescribing physicians making drug interactions an unmanaged risk
______________________________________________
Vulnerability: Anxiety and dependence cycle
What is Happening: Regular cannabis use downregulates the endocannabinoid system's natural CB1 receptors. During periods of abstinence, anxiety and insomnia worsen as the system rebalances driving the person back to cannabis for relief
Why It Matters in Midlife: The cannabis that was started for anxiety and sleep frequently makes both worse over time through this dependence cycle producing a pattern structurally identical to the one described for alcohol in Article 2
______________________________________________
The Sleep Paradox: Why 'It Helps Me Sleep' Is Complicated
Sleep is the primary reason midlife adults report using cannabis and the research on cannabis and sleep is one of the most important and most misrepresented areas in this field. Cannabis, particularly THC, does reliably reduce the time it takes to fall asleep. This effect is real, it is consistent, and it is the reason the habit forms. However, THC also suppresses REM sleep, the phase associated with memory consolidation, emotional processing, and cognitive restoration. Regular cannabis use has been associated with reduced REM sleep and altered sleep architecture, even as subjective sleep quality improves. The brain may feel as though it is sleeping better while measurably losing the most restorative phases of sleep.
More importantly for the midlife user: tolerance to cannabis's sleep-promoting effects develops relatively quickly, requiring higher doses to achieve the same effect. And when cannabis is discontinued after regular use, rebound insomnia which is often more severe than the original sleep problem is a consistent withdrawal effect. The 2024 National Poll on Healthy Aging found that 17 to 22% of regular older adult cannabis users reported tolerance, suggesting that this pattern is already operating in a substantial proportion of the midlife cannabis-for-sleep population.
The clinical consequence is the same as the alcohol-for-sleep pattern: the substance that was solving the sleep problem is now the reason sleep has become impossible without it. The original sleep disorder, the perimenopausal insomnia, the cortisol dysregulation, the anxiety-driven wakening, has not been treated. It has been suppressed and is now inaccessible without chemical assistance. CBT-I, the evidence-based first-line treatment for insomnia, addresses the actual condition. Cannabis addresses a symptom of the condition while creating a new one.
"Cannabis reliably reduces sleep onset time which is often the reason the habit forms. But it suppresses REM sleep and produces tolerance quickly. When discontinued, rebound insomnia, often worse than the original problem, is a consistent withdrawal effect. The cannabis that was treating the sleep problem has become the reason sleep is impossible without it." — Psychiatric Times (2026); National Poll on Healthy Aging (2024)
The Anxiety Trap: How Cannabis Makes Anxiety Worse Over Time
The second primary reason midlife adults use cannabis is anxiety management, and this is where the research is most counterintuitive to users and most clinically important. Cannabis has complex and dose-dependent effects on anxiety. Low doses of THC may produce mild anxiolytic effects in some users. Higher doses, or use in individuals with anxiety sensitivity, commonly produce or worsen anxiety including acute panic, paranoia, and hypervigilance. This dose-anxiety relationship is a reason that many regular cannabis users report needing to stay within a precise dosage window to avoid the anxiety they are trying to manage.
The more clinically significant issue for regular users is the endocannabinoid system adaptation. The brain's CB1 receptors, which mediate many of cannabis's effects, downregulate in response to chronic THC exposure. With fewer available receptors, the brain becomes less capable of producing the natural endocannabinoid-mediated calm that non-using individuals experience as baseline. Between doses, the anxiety floor rises. The cannabis that was managing anxiety is now being used, in increasing quantity, to bring anxiety back to what was previously the natural baseline and the baseline itself has shifted upward because of the use.
A 2025 cannabis research review found that while short-term cannabis use may provide temporary anxiety relief, long-term regular use is associated with increased anxiety sensitivity, higher rates of anxiety disorder, and a specific pattern of anxiety rebound during abstinence. The person who describes being 'less anxious when I use cannabis' may be accurately describing their experience while the cannabis is the reason their anxiety is higher when they are not using it than it would be without the cannabis history.
This is not universal. CBD-dominant products with low THC content have a different risk profile than high-THC products. The relationship between cannabis and anxiety is dose- and product-specific, individual, and genuinely complex. But, the confident assertion that 'cannabis is good for my anxiety' without awareness of the endocannabinoid adaptation mechanism and the rebound pattern is an incomplete clinical picture and one that midlife users deserve to have completed.
Cannabis Use Disorder: How It Presents Differently
Cannabis use disorder (CUD) is a diagnosable condition under the DSM-5, applying the same 11-criterion framework as alcohol use disorder with cannabis-specific content. Approximately 9% of people who use cannabis develop CUD. This is a lower rate than alcohol, but not negligible, particularly as the potency of available cannabis products has increased significantly over the past two decades.
CUD in midlife adults presents differently from the stereotype of cannabis dependence in younger users. The midlife user with CUD is typically using daily or near-daily, primarily via edibles or vaping rather than smoking, with a clear medical rationale (sleep, anxiety, pain) that makes the use feel categorically different from recreational use. They are not using in social contexts or for enhancemen, they are using privately, consistently, in the evening, as the primary management strategy for the symptoms that are otherwise disrupting their functioning.
The diagnostic criteria most commonly met in this population are tolerance (needing more to achieve the same sleep or anxiety effect), withdrawal (the insomnia and anxiety that emerge when not using), and continued use despite awareness that it may be worsening sleep quality or cognitive function. The criteria least commonly met are the social and role impairment criteria because the midlife user, like the midlife high-functioning alcohol user, maintains function significantly longer.
A clinically important note: cannabis withdrawal, while not medically dangerous in the way alcohol withdrawal can be, produces a consistent syndrome of insomnia, irritability, anxiety, decreased appetite, and restlessness lasting one to two weeks after cessation of regular use. This withdrawal syndrome is frequently mistaken for the return of the original condition; the insomnia and anxiety that cannabis was being used to treat. The person who stops cannabis and experiences terrible sleep and elevated anxiety may conclude that they cannot function without it, when what they are experiencing is the withdrawal phase that resolves if the cessation is maintained.
What Honest Assessment of Midlife Cannabis Use Looks Like
The honest clinical assessment of midlife cannabis use requires the same framework as the honest assessment of alcohol use, and is even less commonly applied, because the cultural and clinical acceptance of cannabis use has outpaced the clinical infrastructure for assessing it.
The key questions for a midlife adult using cannabis regularly: Has the dose needed to achieve the same effect increased over time? What happens when you don't use it? Can you sleep, can you manage anxiety at your baseline, or have both significantly worsened? Have you tried to use less or stop and found it harder than expected? Is the cannabis actually improving your cognitive function (as symptom relief) or worsening it (as regular THC exposure)? Have you told your prescribing physicians, including your menopause-specialized clinician if relevant, about your cannabis use? And the question most directly parallel to the alcohol gray zone question, has the cannabis become necessary for functioning, rather than helpful to it?
These questions are not condemnations of cannabis use. They are the questions that allow a midlife adult to make an informed decision about a pharmacologically active substance they are using regularly with accurate information about what it is doing to their brain, their sleep, their anxiety system, and their cognitive function rather than the incomplete information that most of them are currently relying on.
For those who recognize the gray zone pattern in their cannabis use, the tolerance, the rebound, the inability to sleep without it, the treatment approaches that work are substantially the same as those that work for alcohol gray zone use: CBT for the underlying anxiety and sleep disorder, gradual dose reduction with clinical support, and explicit attention to the endocannabinoid rebound period that makes the first two to four weeks of reduction particularly difficult. Abstinence is not the only goal; informed, reduced, intentional use is a legitimate clinical target for many midlife users who do not have full CUD.
About the Author
Dr. Julie Rashkis is a licensed psychologist and Menopause Society Certified Practitioner with over 20 years of clinical experience. She works with midlife adults navigating the cannabis gray zone providing the honest, non-judgmental clinical assessment that most providers are not yet equipped to offer. She is the founder of Therapy for Midlife, a virtual practice licensed in California and Wisconsin, seeing clients across all PSYPACT-participating states.
www.therapyformidlife.com | Book a free consultation
To learn more about Substance Misuse in Midlife
References
1. Patrick, M. E., Terry-McElrath, Y. M., & Jang, J. B. (2025). Trends in early and late midlife substance use through 2024 from the US
Monitoring the Future Panel Study. PMC12762002.
2. Huhn, A. S., et al. (2025). Older adults' perspectives on and experiences with cannabis use: Results from the 2024 National Poll on
Healthy Aging. PMC12763590.
3. Phillipps, H. S., et al. (2025). How cannabis use is associated with the physical and mental health of older adults: A US
population-based study. International Journal of Mental Health and Addiction. Springer.
4. Meier, M. H., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the
National Academy of Sciences, 109(40). [Dunedin cohort]
5. Psychiatric Times. (2026). Cannabis use is booming in older adults: Are we ready? psychiatrictimes.com.
6. Moore, A., et al. (2022). Correlates of cannabis use among middle-aged and older adults: Findings from NESARC-III. PMC9771400.
7. Bhattacharyya, S., et al. (2025). Cannabis update 2025: Research on depression, anxiety, PTSD, sleep and cognition. Psychiatry &
Psychotherapy Podcast.
8. Bonn-Miller, M. O., et al. (2014). Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder
symptoms among veterans. Psychological Trauma, 6(5), 557-563.
9. Hasin, D. S., et al. (2015). DSM-5 criteria for substance use disorders: Recommendations and rationale. American Journal of
Psychiatry, 170(8), 834-851.
10. Epidemiology of cannabis use among middle-aged and older adults in the United States. (2024). MedRxiv preprint.
medrxiv.org/content/10.1101/2024.10.11.24315329.
11. Age differences in patterns of cannabis use among an online US sample of adults who consume cannabis frequently. (2024).
PMC11670332.
